Can one HIV pill a week replace daily therapy? Gilead and Merck’s Phase 3 data raise the stakes
Gilead and Merck’s weekly HIV pill preserved suppression in two Phase 3 trials, strengthening the case for regulatory filings.
Pharma & Biotech